Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Semaglutide's heart benefits explored in new study

NCT ID NCT07190144

Knowledge-focused Sponsor: Ekrem Bilal Karaayvaz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed observational study examined whether semaglutide, a drug used for diabetes and weight loss, improves blood flow in the coronary arteries. Researchers measured coronary flow reserve in 122 diabetic and non-diabetic patients before and after 3 months of treatment. The study aimed to see if the drug enhances heart vessel function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this could show that semaglutide improves blood flow to the heart, pointing toward a new benefit of the drug beyond diabetes and weight loss.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also completed, so no new data is being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

122 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who were diabetic and non-diabetic and planned to start semaglutide has referred to cardiology clinic for the study.

Ages

28 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who were planned to start semaglutide. Exclusion Criteria: * Ischemic heart disease * Previous stent implantation or coronary bypass * Heart failure * Cardiomyopathies * Inflammatory diseases * Autoimmune rheumatic disease * Chronic liver and renal insufficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight The study focused on the vascular effects of semaglutide in both diabetic and non-diabetic patients

Contacts and locations

Locations

  • Medicana International Istanbul Hospital

    Istanbul, 34520, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.